A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence

Addiction

Volumn 104, Issue 2, 2009, Pages 224-233

  Shearer, James ^a   Darke, Shane ^a   Rodgers, Craig ^b   Slade, Tim ^a   Van Beek, Ingrid ^b   Lewis, John ^c   Brady, Donna ^d   McKetin, Rebecca ^a   Mattick, Richard P ^a   Wodak, Alex ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY EYE HOSPITAL   (Australia)

^c Pacific Laboratory Medicine Services   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

Abuse liability; Counselling; Methamphetamine dependence; Modafinil; Randomised controlled trial; Safety; Treatment

Indexed keywords

METHAMPHETAMINE; MODAFINIL; PLACEBO;

ADULT; ANXIETY DISORDER; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PANIC; PATIENT COMPLIANCE; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH DISCOMFORT; STOMACH PAIN; SUBSTANCE ABUSE; SYSTOLIC BLOOD PRESSURE; THOUGHT DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ADULT; AMPHETAMINE-RELATED DISORDERS; AUSTRALIA; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SEVERITY OF ILLNESS INDEX; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58349093949     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2008.02437.x     Document Type: Article

References (46)

1. McKetin R., Kozel N., Douglas J., Ali R., Vicknasingam B., Lund J. et al. The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 2008 27 : 220.
2. Maxwell J., Rutowski B. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators. Drug Alcohol Rev 2008 27 : 229.
3. Degenhardt L., Roxburgh A., Black E., Bruno R., Campbell G., Kinner S. et al. The epidemiology of methamphetamine use and harm in Australia. Drug Alcohol Rev 2008 27 : 243.
4. Darke S., Kaye S., McKetin R., Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008 27 : 253.
5. Everitt B. J., Wolf M. E. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci 2002 22 : 3312 20.
6. Volkow N. D., Chang L., Wang G.-J., Fowler J. S., Leonido-Yee M., Franceschi D. et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001 158 : 377 82.
7. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999 22 : 521 7.
8. White F., Kalivas P. Neuroadaptions involved in amphetamine and cocaine addiction. Drug Alcohol Depend 1998 51 : 141 53.
9. Trudeau L.-E. Glutamate co-transmission as an emerging concept in monoamine neuron function. J Psychiatry Neurosci 2004 29 : 296 310.
10. Kalivas P., McFarland K., Bowers S., Szumlinski K., Xi Z., Baker D. Glutamate transmission and addiction to cocaine. Ann N Y Acad Sci 2003 1003 : 169 75.
11. Shearer J., Gowing L. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev 2004 23 : 203 11.
12. Srisurapanont M., Jarusuraisin N., Kittirattanapaiboon P. Treatment for Amphetamine Dependence and Abuse (Cochrane Review). Oxford : The Cochrane Library, Update Software 2001.
13. Murillo-Rodriguez E., Haro R., Palomero-Rivero M., Millan-Aldaco D., Drucker-Colin R. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 2007 176 : 353 7.
14. Madras B. K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L. et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006 319 : 561 9.
15. Willie J., Renthal W., Chemelli R., Miller M., Scammell T., Yanagisawa M. et al. Modafinil more effectively induces wakefulness in norexin-null mice than wild-type littermates. Neuroscience 2005 130 : 983 95.
16. Scammell T., Estabrooke I., McCarthy M., Chemelli R., Yanagisawa M., Miller M. et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000 20 : 8620 8.
17. Dackis C. New treatments for cocaine abuse. Drug Discov Today 2005 2 : 79 86.
18. Stoops W., Lile J., Fillmore M., Glaser P., Rush C. Reinforcing effects of modafinil: influence of dose and behavioural demands following drug administration. Psychopharmacology 2005 182 : 186 93.
19. Robertson P., Hellriegel E. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003 42 : 123 37.
20. O'Brien C., Dackis C., Kampman K. Does modafinil produce euphoria? Am J Psychiatry 2006 163 : 6.
21. McGregor C., Srisurapanont M., Mitchell A., Wickes W., White J. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008 35 : 334 42.
22. Jasinski D., Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000 23 : 149 56.
23. Dackis C., Lynch K., Yu E., Samaha F., Kampman K., Cornish J. et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003 70 : 29 37.
24. Malcolm R., Swayngim K., Donovan J., Devane C., Elkashef A., Chiang N. et al. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 2006 32 : 577 87.
25. Dackis C., Kampman K., Lynch K., Pettinati H., O'Brien C. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005 30 : 205 11.
26. WHO. Composite International Diagnostic Interview. Sydney : WHO Collaborating Centre for Mental Health and Substance Abuse 1997.
27. Baker A., Lee N., Claire M., Lewin T., Grant T., Pohlman S. et al. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction 2005 100 : 367 78.
28. Darke S., Hall W., Wodak A., Heather N., Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992 87 : 733 42.
29. Barrowcliff A., Champney-Smith J., McBride A. Use of a modified version of the Opiate Treatment Index with amphetamine users: validation and pilot evaluation of a prescribing service. J Subst Use 1999 14 : 98 103.
30. Del Boca F., Darkes J. Enhacing the validity and utility of randomized clinical trials in addictions treatment research: II. Participant samples and assessment. Addiction 2007 102 : 1194 203.
31. Derogatis L. Brief Symptom Inventory (BSI): Administration, Scoring and Procedures Manual. Minneapolis : National Computer Systems 1993.
32. Gossop M., Darke S., Griffiths P., Hando J., Powis B., Hall W. et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995 90 : 607 14.
33. Lewis J. Working to recognised standards: a prerequisite for drug testing in Australia. Ther Drug Monit 2002 24 : 182 6.
34. Vickers A., Altman D. Analysing controlled trials with baseline and follow up measurements. BMJ 2001 323 : 1123 4.
35. Zeger S., Liang K.-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986 42 : 121 30.
36. Zeger S., Liang K.-Y., Albert P. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988 44 : 1049 60.
37. Mazumdar S., Tang G., Houck P., Dew M., Begley A., Scott J. et al. Statistical analysis of longitudinal psychiatric data with dropouts. J Psychiatr Res 2007 41 : 1032 41.
38. Twisk J. Applied Longitudinal Data Analysis for Epidemiology. Cambridge : Cambridge University Press 2003.
39. Mackris A., Rush C., Frederich R., Kelly T. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004 42 : 185 95.
40. Broughton R. J., Fleming J. A. E., George C. F. P., Hill J. D., Kryger M. H., Moldofsky H. et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997 49 : 444 51.
41. Guilleminault C., Aftab F., Karadeniz D., Philip P., Leger D. Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. Eur J Neurol 2000 7 : 381 4.
42. Girish M., Shephard J., Silber M. Change from conventional stimulants to modafinil in patients with narcolepsy or idiopathic hypersomnia. Sleep 2000 23 : A302.
43. Schmitz J., Mooney M., Moeller F., Stotts A., Green C., Grabowski J. et al. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral platform. Drug Alcohol Depend 2008 94 : 142 50.
44. Cruikshank C., Montebello M., Dyer K., Quigley A., Blaszczyk J., Tomkins S. et al. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev 2008 27 : 326 33.
45. Sinha R., Garcia M., Paliwal P., Kreek M. J., Rounsaville B. J. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry 2006 63 : 324 31.
46. Volkow N., Fowler J. Addiction, a disease of complusion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 2000 10 : 318 25.